Cochlear logo

COH - Cochlear Share Price

A$195.65 4.4  2.3%

Last Trade - 5:10am

Sector
Healthcare
Size
Large Cap
Market Cap £7.12bn
Enterprise Value £6.99bn
Revenue £748.7m
Position in Universe 44th / 1843
Bullish
Bearish
Unlock COH Revenue
Momentum
Relative Strength (%)
1m -3.87%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
925.6 1,131 1,254 1,364 1,427 1,321 1,461 1,698 +7.4%
+32.9 +31.0 +14.0 +8.5 +9.1 +16.9 -39.2 +35.7
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, CochlearLimited revenues decreased 7% to A$1.32B. Net loss totaledA$238.3M vs. income of A$276.7M. Revenues reflect EMEAsegment decrease of 8% to A$479.6M, Americas segmentdecrease of 6% to A$650.3M. Net loss reflects Selling,marketing and general expenses increase of 4% to A$470M(expense), Net foreign exchange loss increase of 55% toA$6.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for COH
Graphical History

Revenue

COH Revenue Unlock COH Revenue

Net Income

COH Net Income Unlock COH Revenue

Normalised EPS

COH Normalised EPS Unlock COH Revenue

PE Ratio Range

COH PE Ratio Range Unlock COH Revenue

Dividend Yield Range

COH Dividend Yield Range Unlock COH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
COH EPS Forecasts Unlock COH Revenue
Profile Summary

Cochlear Ltd is an Australia-based company that provides implantable hearing solutions. The Company provides bone conduction implants for people with conductive hearing loss, mixed hearing loss and single-sided deafness. Its segments include Americas, EMEA and Asia Pacific. Americas includes the United States, Canada and Latin America. EMEA includes Europe, Middle East and Africa. Asia Pacific includes Australasia and Asia. Its implantable hearing solution portfolio includes Cochlear implants, such as Cochlear Nucleus Profile Plus with Slim Modiolar Electrode (CI632), Cochlear Nucleus Kanso Sound Processor (CP950), Cochlear Nucleus 7 Sound Processor (CP1000) and Cochlear Nucleus smart application and bone conduction implants, such as Cochlear Baha 5, Baha 5 Power and Baha 5 SuperPower, Cochlear Baha SoundArc, Cochlear Baha Smart App and Cochlear Carina System.

Directors
Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated June 8, 1983
Public Since December 4, 1995
No. of Shareholders: 42,531
No. of Employees: 4,000
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index S&P/ASX 50 , S&P/ASX All Ordinaries , S&P/ASX 100 , S&P/ASX 200 , S&P/ASX 300 , FTSE Developed Asia Pacific , FTSE Developed Asia Pacific Ex Japan ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 65,687,402
Free Float (0.0%)
Eligible for
ISAs
SIPPs
COH Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for COH
Upcoming Events for COH
Tuesday 16th February, 2021
Half Year 2021 Cochlear Ltd Earnings Release
Frequently Asked Questions for Cochlear
What is the Cochlear share price?

As of 5:10am, shares in Cochlear are trading at A$195.65, giving the company a market capitalisation of £7.12bn. This share price information is delayed by 15 minutes.

How has the Cochlear share price performed this year?

Shares in Cochlear are currently trading at A$195.65 and the price has moved by -20.56% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cochlear price has moved by -17.57% over the past year.

What are the analyst and broker recommendations for Cochlear?

Of the analysts with advisory recommendations for Cochlear, there are there are currently 1 "buy" , 4 "hold" and 3 "sell" recommendations. The overall consensus recommendation for Cochlear is Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Cochlear next release its financial results?

Cochlear is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Cochlear dividend yield?

The Cochlear dividend yield is 0.84% based on the trailing twelve month period.

Does Cochlear pay a dividend?

Last year, Cochlear paid a total dividend of 1.6, and it currently has a trailing dividend yield of 0.84%. Looking ahead, Cochlear has not announced an ex-dividend date yet.

When does Cochlear next pay dividends?

Cochlear has yet to annouce their ex-dividend date. The historic dividend yield on Cochlear shares is currently 0.84%.

How do I buy Cochlear shares?

To buy shares in Cochlear you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cochlear?

Shares in Cochlear are currently trading at A$195.65, giving the company a market capitalisation of £7.12bn.

Where are Cochlear shares listed? Where are Cochlear shares listed?

Here are the trading details for Cochlear:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: COH
What kind of share is Cochlear?

Based on an overall assessment of its quality, value and momentum, Cochlear is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cochlear share price forecast 2021?

Shares in Cochlear are currently priced at A$195.65. At that level they are trading at 5.38% discount to the analyst consensus target price of 0.00.

Analysts covering Cochlear currently have a consensus Earnings Per Share (EPS) forecast of 3.37 for the next financial year.

How can I tell whether the Cochlear share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cochlear. Over the past six months, the relative strength of its shares against the market has been -13.14%. At the current price of A$195.65, shares in Cochlear are trading at -3.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cochlear PE Ratio?

The Cochlear PE ratio based on its reported earnings over the past 12 months is 34.52. The shares are currently trading at A$195.65.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Cochlear?

Cochlear's management team is headed by:

Richard Brook - CEX
Roderic Holliday-Smith - NEC
Andrew Denver - NED
Yasmin Allen - NID
Diggory Howitt - PRE
Glen Boreham - NID
Stuart Sayers - CFO
Anthony Bishop - CEX
Dean Phizacklea - SVP
Tony Manna - CEX
Rom Mendel - CEX
Greg Bodkin - SVP
Jennifer Hornery - SVP
Michael Daniell - NED
Brian Kaplan - SVP
Who are the major shareholders of Cochlear?

Here are the top five shareholders of Cochlear based on the size of their shareholding:

Baillie Gifford & Co. Investment Advisor
Percentage owned: 6% (3.94m shares)
Veritas Asset Management LLP Investment Advisor/Hedge Fund
Percentage owned: 5.62% (3.70m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.48% (3.60m shares)
Hyperion Asset Management Limited Investment Advisor
Percentage owned: 4.4% (2.89m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.21% (2.11m shares)
Similar to COH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.